Vaccine committee considers changes to childhood schedule, NY Times reports

Advisers to Health Secretary Robert F. Kennedy Jr. are considering major revisions to the childhood vaccination schedule, including delaying or potentially removing the routine hepatitis B shot given at birth, The New York Times’ Apoorva Mandavilli reports. Although not legally binding, their decisions could significantly influence insurance coverage and public health guidelines, with members also expected to debate vaccine ingredients and the use of combination shots, Mandavilli writes. Publicly traded companies that could be impacted include Moderna (MRNA), Pfizer (PFE), BioNTech (BNTX), Novavax (NVAX), AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Roche (RHHBY), and Sanofi (SNY).